Ophthalmology

Biology and Look-Alike Conditions

At a Glance

Gyrate atrophy is an inherited eye disorder caused by changes in both copies of the OAT gene. The resulting high ornithine level can damage the retinal pigment epithelium, choroid, and retina; blood, imaging, and genetic tests help distinguish it from similar retinal diseases.

Gyrate Atrophy is a unique condition that sits at the intersection of ophthalmology and metabolic medicine. While it may look similar to other retinal diseases at first glance, its underlying biology and the specific way it changes the eye are distinct. Understanding these differences is crucial for ensuring the correct diagnosis and starting the right treatment.

The OAT Gene and the “Ornithine Overload”

The biological root of Gyrate Atrophy is a mutation in the OAT gene. This gene is responsible for producing an enzyme called ornithine aminotransferase ^[1]. This enzyme typically lives inside the mitochondria (the powerhouses of your cells) and helps convert an amino acid called ornithine into other useful substances, like glutamate ^[1]^[2].

When this enzyme is missing or broken, ornithine cannot be processed. It begins to build up in the blood—a state called hyperornithinemia—reaching levels many times higher than normal ^[3].

How High Ornithine Damages the Eye

While the entire body is exposed to high ornithine, the eyes are particularly vulnerable. Research indicates that the Retinal Pigment Epithelium (RPE)—a single layer of cells that nourishes the retina—appears to be an early site of damage ^[2].

Proposed Mechanisms: Current theories propose that the high levels of ornithine cause “stress” within the RPE cells’ mitochondria, disrupting their energy production and antioxidant defenses ^[4].
Secondary Effects: The buildup may also interfere with other amino acids like lysine or lead to the production of toxic byproducts that cause oxidative damage to the eye’s tissues ^[4]^[5].
Chorioretinal Degeneration: Clinically, it is established that as the RPE cells die, the choroid (the blood vessel layer underneath) and the retina (the light-sensing layer above) also begin to waste away (atrophy) ^[1]^[6].

Differentiating “Look-Alike” Conditions

Because Gyrate Atrophy causes night blindness and a loss of side vision, it is often initially mistaken for more common conditions like Retinitis Pigmentosa (RP) or Choroideremia. However, there are key differences that doctors look for.

Feature	Gyrate Atrophy (GA)	Retinitis Pigmentosa (RP)	Choroideremia (CHM)
Genetic Cause	OAT gene (Autosomal Recessive) ^[7]	Many genes (Variable inheritance) ^[8]	CHM gene (X-linked; mostly males, but female carriers can show findings) ^[9]
Metabolic Marker	Marked Hyperornithinemia ^[3]	Typically do not cause marked hyperornithinemia	Typically do not cause marked hyperornithinemia
Retinal Appearance	Sharply defined, scalloped patches of atrophy ^[6]	“Bone-spicule” pigment clumps; thin blood vessels ^[10]	Patchy RPE loss; “moth-eaten” appearance ^[11]
Typical Onset	Early childhood; high myopia common ^[12]	Variable; childhood through adulthood	Childhood night blindness ^[13]

Why Precision Matters

Distinguishing these conditions is not just academic; it changes how you are treated.

Metabolic Testing: A simple blood test for plasma amino acids can often identify Gyrate Atrophy by revealing high ornithine levels ^[12]. Neither RP nor Choroideremia will show this marked metabolic change, though other rare metabolic conditions can raise ornithine.
Imaging Patterns: Doctors use Widefield Imaging to look at the far edges of the retina. In GA, the atrophic patches have a characteristic “scalloped” or lobed border that is very different from the pigment patterns seen in RP ^[6]^[14].
Genetic Confirmation: Because GA is autosomal recessive, a child must inherit two mutated copies of the OAT gene (one from each parent) ^[7]. Confirming the specific gene mutation through a retinal gene panel is a highly valuable tool for diagnosis ^[15].

If a diagnosis is uncertain, asking for both a metabolic blood test and a comprehensive genetic panel can provide the clarity needed to manage the condition effectively.

Common questions in this guide

What causes gyrate atrophy of the choroid and retina?

Gyrate atrophy is caused by disease-causing changes in both copies of the OAT gene. These changes reduce ornithine aminotransferase, allowing ornithine to build up in the blood and contributing to damage of the retinal pigment epithelium, choroid, and retina.

How can gyrate atrophy be distinguished from retinitis pigmentosa or choroideremia?

A plasma amino acid test may show the markedly high ornithine level associated with gyrate atrophy, while retinitis pigmentosa and choroideremia usually do not cause this change. Widefield imaging may show sharply defined, scalloped atrophic patches, and genetic testing can help confirm OAT-related disease or identify another inherited retinal condition. Other rare metabolic conditions can also raise ornithine, so results should be interpreted together.

What tests are used to confirm gyrate atrophy?

Doctors may order a plasma amino acid test to measure ornithine and a retinal gene panel to look for disease-causing variants in both copies of OAT. Eye examination and widefield imaging help identify the characteristic scalloped areas of chorioretinal atrophy. The combination of metabolic, imaging, and genetic findings can clarify the diagnosis.

Why is ornithine high in gyrate atrophy?

The OAT gene normally helps cells make ornithine aminotransferase, an enzyme in mitochondria that processes ornithine into other substances. When the enzyme is missing or not working, ornithine cannot be processed normally and accumulates in the blood.

What do scalloped areas on retinal imaging mean?

In gyrate atrophy, widefield imaging can show sharply defined, scalloped or lobed patches where the choroid and retina have atrophied. This pattern helps eye specialists distinguish gyrate atrophy from pigment patterns seen in conditions such as retinitis pigmentosa, but imaging is interpreted with blood and genetic testing.

What does autosomal recessive inheritance mean for my family?

A child develops gyrate atrophy when they inherit two altered copies of OAT, one from each parent. Parents may carry one altered copy without having the condition, so a genetics professional can explain testing and recurrence risks for siblings and relatives.

Get notified when new evidence is published on Gyrate atrophy of choroid and retina.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (15)

1
Molecular and cellular basis of ornithine δ-aminotransferase deficiency caused by the V332M mutation associated with gyrate atrophy of the choroid and retina.
Montioli R, Desbats MA, Grottelli S, et al.
Biochimica et biophysica acta. Molecular basis of disease 2018; (1864(11)):3629-3638 doi:10.1016/j.bbadis.2018.08.032.
PMID: 30251682
2
Ocular Tissue-Specific Amino Acid Metabolism in Gyrate Atrophy.
Puja A, Lu J, Du J
Advances in experimental medicine and biology 2025; (1468()):279-284 doi:10.1007/978-3-031-76550-6_46.
PMID: 39930209
3
Deficit of human ornithine aminotransferase in gyrate atrophy: Molecular, cellular, and clinical aspects.
Montioli R, Bellezza I, Desbats MA, et al.
Biochimica et biophysica acta. Proteins and proteomics 2021; (1869(1)):140555 doi:10.1016/j.bbapap.2020.140555.
PMID: 33068755
4
Early proteomic and metabolic signatures of liver and eye in OAT-deficient mice.
Puja A, Xu R, Mascari I, et al.
Experimental eye research 2026; (271()):111140 doi:10.1016/j.exer.2026.111140.
PMID: 42373003
5
Spermidine Oxidation-Mediated Degeneration of Retinal Pigment Epithelium in Rats.
Ohashi K, Kageyama M, Shinomiya K, et al.
Oxidative medicine and cellular longevity 2017; (2017()):4128061 doi:10.1155/2017/4128061.
PMID: 28367269
6
Inborn Errors of Metabolism: Gyrate Atrophy.
Tsang SH, Aycinena ARP, Sharma T
Advances in experimental medicine and biology 2018; (1085()):183-185 doi:10.1007/978-3-319-95046-4_37.
PMID: 30578510
7
Extending diagnostic practices in gyrate atrophy: Enzymatic characterization and the development of an in vitro pyridoxine responsiveness assay.
Balfoort BM, Pampalone G, Ruiter JPN, et al.
Molecular genetics and metabolism 2024; (143(1-2)):108542 doi:10.1016/j.ymgme.2024.108542.
PMID: 39053126
8
RP2-Associated X-linked Retinopathy: Clinical Findings, Molecular Genetics, and Natural History.
Georgiou M, Robson AG, Jovanovic K, et al.
Ophthalmology 2023; (130(4)):413-422 doi:10.1016/j.ophtha.2022.11.015.
PMID: 36423731
9
PHENOTYPING CHOROIDEREMIA AND ITS CARRIER STATE WITH MULTIMODAL IMAGING TECHNIQUES.
Ma KK, Lin J, Boudreault K, et al.
Retinal cases & brief reports 2017; (11 Suppl 1()):S178-S181 doi:10.1097/ICB.0000000000000419.
PMID: 27599108
10
Retained cone-responses in homozygous start codon variant in KIZ-associated retinitis pigmentosa.
Kong MD, O'Connell M, Exinor A, et al.
Documenta ophthalmologica. Advances in ophthalmology 2026; (152(3)):409-414 doi:10.1007/s10633-025-10066-7.
PMID: 41557064
11
Clinical and Genetic Features of Choroideremia in Childhood.
Khan KN, Islam F, Moore AT, Michaelides M
Ophthalmology 2016; (123(10)):2158-65.
PMID: 27506488
12
Widefield Retinal Imaging in Gyrate Atrophy: Correlation of Structural, Biochemical, and Functional Characteristics.
Padhy SK, Parameswarappa DC, Sharma S, et al.
Ophthalmology. Retina 2025; (9(4)):392-401 doi:10.1016/j.oret.2024.10.016.
PMID: 39447872
13
Natural History of the Central Structural Abnormalities in Choroideremia: A Prospective Cross-Sectional Study.
Aleman TS, Han G, Serrano LW, et al.
Ophthalmology 2017; (124(3)):359-373 doi:10.1016/j.ophtha.2016.10.022.
PMID: 27986385
14
Ultrawide field fluorescein angiogram in a family with gyrate atrophy and foveoschisis.
Tripathy K, Chawla R, Sharma YR, Gogia V
Oman journal of ophthalmology 2016; (9(2)):104-6 doi:10.4103/0974-620X.184529.
PMID: 27433038
15
The coincidence of two ultra-rare hereditary eye diseases: gyrate atrophy and Kjer optic atrophy - a surprising diagnosis based on next-generation sequencing.
Skorczyk-Werner A, Raczynska D, Wawrocka A, et al.
Intractable & rare diseases research 2021; (10(3)):202-206 doi:10.5582/irdr.2021.01042.
PMID: 34466343

This page explains the biology and diagnostic differences of gyrate atrophy for informational purposes only and does not constitute medical advice. An ophthalmologist, genetic specialist, or metabolic specialist should interpret your test results and care plan.